|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - NovoCure Ltd (NVCR)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-05-10 Sale |
2019-05-14 4:08 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $49.79 | $248,950 | 65,000 (Direct) |
View |
| 2019-05-08 Sale |
2019-05-10 4:13 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
31,460 | $47.37 | $1,490,386 | 896,463 (Direct) |
View |
| 2019-05-07 Sale |
2019-05-09 4:20 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
64,316 | $47.6 | $3,061,143 | 927,923 (Direct) |
View |
| 2019-05-06 Sale |
2019-05-07 4:28 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
29,038 | $48.07 | $1,395,915 | 874,703 (Direct) |
View |
| 2019-05-02 Sale |
2019-05-06 5:48 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
29,966 | $45.21 | $1,354,643 | 844,973 (Direct) |
View |
| 2019-05-01 Sale |
2019-05-03 4:15 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
1,204 | $43.79 | $52,729 | 78,546 (Direct) |
View |
| 2019-04-10 Sale |
2019-04-12 4:05 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $45.95 | $229,750 | 65,000 (Direct) |
View |
| 2019-04-01 Sale |
2019-04-03 4:25 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
49,891 | $47.34 | $2,362,053 | 207,549 (Direct) |
View |
| 2019-03-11 Sale |
2019-03-12 4:56 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $48.31 | $241,550 | 69,743 (Direct) |
View |
| 2019-03-04 Sale |
2019-03-06 4:18 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
90,000 | $53.94 | $4,854,312 | 315,897 (Direct) |
View |
| 2019-03-04 Sale |
2019-03-06 4:17 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $55.89 | $909,286 | 250,025 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:15 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $55.57 | $5,556,582 | 333,757 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:14 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $55.01 | $1,375,275 | 85,000 (Direct) |
View |
| 2019-03-01 Sale |
2019-03-04 4:13 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
40,586 | $55.63 | $2,257,698 | 45,961 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:52 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
3,097 | $53.68 | $166,247 | 921,403 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:36 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
3,288 | $53.68 | $176,500 | 69,552 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:35 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
2,397 | $53.68 | $128,671 | 171,702 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:32 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
1,558 | $53.68 | $83,633 | 26,797 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:31 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $54.4 | $49,119 | 353,887 (Direct) |
View |
| 2019-02-27 Sale |
2019-03-01 4:30 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
2,368 | $53.68 | $127,114 | 39,203 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 6:00 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
12,230 | $53.63 | $655,870 | 177,758 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:58 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,647 | $53.63 | $1,000,001 | 80,482 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:56 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
6,377 | $53.63 | $341,986 | 30,087 (Direct) |
View |
| 2019-02-22 Sale |
2019-02-26 5:54 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
9,325 | $53.63 | $500,081 | 42,972 (Direct) |
View |
| 2019-02-12 Sale |
2019-02-14 5:10 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
50,000 | $51.46 | $2,573,000 | 203,262 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-05-10 Exercise |
2019-05-14 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 65,000 (Direct) |
View |
| 2019-05-10 Exercise |
2019-05-14 4:08 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 65,000 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:16 pm |
2029-05-08 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
33,052 | $47.56 | 33,052 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:16 pm |
2029-05-08 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
20,000 | $47.56 | 33,052 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:15 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
29,320 | $47.56 | 29,320 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:15 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
20,000 | $47.56 | 29,320 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:14 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
36,650 | $47.56 | 36,650 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:14 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
20,000 | $47.56 | 36,650 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:13 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
115,060 | $47.56 | 896,463 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:13 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
35,000 | $47.56 | 896,463 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:11 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
91,515 | $47.56 | 91,515 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:11 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
20,000 | $47.56 | 91,515 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:10 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
115,060 | $47.56 | 115,060 (Direct) |
View |
| 2019-05-08 Option Award |
2019-05-10 4:10 pm |
N/A 2029-05-08 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
35,000 | $47.56 | 115,060 (Direct) |
View |
| 2019-05-07 Exercise |
2019-05-09 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $48.92 | 927,923 (Direct) |
View |
| 2019-05-07 Exercise |
2019-05-09 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $47.62 | 927,923 (Direct) |
View |
| 2019-05-07 Exercise |
2019-05-09 4:20 pm |
2019-05-07 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $0 | 927,923 (Direct) |
View |
| 2019-05-07 Exercise |
2019-05-09 4:20 pm |
2019-05-08 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $0 | 927,923 (Direct) |
View |
| 2019-05-06 Exercise |
2019-05-07 4:28 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $48.89 | 874,703 (Direct) |
View |
| 2019-05-06 Exercise |
2019-05-07 4:28 pm |
2019-05-06 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $0 | 874,703 (Direct) |
View |
| 2019-05-02 Exercise |
2019-05-06 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $43.28 | 844,973 (Direct) |
View |
| 2019-05-02 Exercise |
2019-05-06 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $44.6 | 844,973 (Direct) |
View |
| 2019-05-02 Exercise |
2019-05-06 5:48 pm |
2019-05-02 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $0 | 844,973 (Direct) |
View |
| 2019-05-02 Exercise |
2019-05-06 5:48 pm |
2019-05-03 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
58,768 | $0 | 844,973 (Direct) |
View |
| 2019-05-01 Exercise |
2019-05-03 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
2,334 | $44.07 | 78,546 (Direct) |
View |
| 2019-05-01 Exercise |
2019-05-03 4:15 pm |
2019-05-01 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
2,334 | $0 | 78,546 (Direct) |
View |
| 2019-04-10 Exercise |
2019-04-12 4:05 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 65,000 (Direct) |
View |
| 2019-04-10 Exercise |
2019-04-12 4:05 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 65,000 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
21,875 | $14.37 | 207,549 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
12,500 | $11.46 | 207,549 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
15,516 | $14.37 | 207,549 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
21,875 | $14.37 | 207,549 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
12,500 | $11.46 | 207,549 (Direct) |
View |
| 2019-04-01 Exercise |
2019-04-03 4:25 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
15,516 | $14.37 | 207,549 (Direct) |
View |
| 2019-03-28 Exercise |
2019-04-01 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
23,652 | $6.72 | 76,212 (Direct) |
View |
| 2019-03-28 Exercise |
2019-04-01 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,869 | $7.03 | 76,212 (Direct) |
View |
| 2019-03-28 Exercise |
2019-04-01 4:15 pm |
N/A 2022-07-22 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
23,652 | $6.72 | 76,212 (Direct) |
View |
| 2019-03-28 Exercise |
2019-04-01 4:15 pm |
N/A 2023-02-19 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,869 | $7.03 | 76,212 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:33 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
16,369 | $0 | 53,204 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:33 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
29,969 | $47.04 | 53,204 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:25 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
20,461 | $0 | 86,725 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:25 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
37,461 | $47.04 | 86,725 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:24 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
24,554 | $0 | 942,860 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:24 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
44,953 | $47.04 | 942,860 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
18,452 | $0 | 43,691 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:23 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
33,783 | $47.04 | 43,691 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:07 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
24,554 | $0 | 258,311 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:07 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
44,953 | $47.04 | 258,311 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:05 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
16,369 | $0 | 185,674 (Direct) |
View |
| 2019-03-22 Option Award |
2019-03-26 4:05 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
29,969 | $47.04 | 185,674 (Direct) |
View |
| 2019-03-11 Exercise |
2019-03-12 4:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 69,743 (Direct) |
View |
| 2019-03-11 Exercise |
2019-03-12 4:56 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 69,743 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,766 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
40,000 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
31,234 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
18,766 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
40,000 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:18 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
31,234 | $3.44 | 315,897 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $14.37 | 250,025 (Direct) |
View |
| 2019-03-04 Exercise |
2019-03-06 4:17 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
16,268 | $14.37 | 250,025 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $14.37 | 333,757 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:15 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $14.37 | 333,757 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $3.44 | 85,000 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:14 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
25,000 | $3.44 | 85,000 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,439 | $11.46 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,250 | $7.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,897 | $21.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,439 | $11.46 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,250 | $7.15 | 45,961 (Direct) |
View |
| 2019-03-01 Exercise |
2019-03-04 4:13 pm |
N/A 2028-02-26 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,897 | $21.15 | 45,961 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:52 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
9,260 | $52.9 | 921,403 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:52 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
9,260 | $0 | 921,403 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:36 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
7,717 | $52.9 | 69,552 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:36 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
7,717 | $0 | 69,552 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
6,174 | $52.9 | 171,702 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:35 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
6,174 | $0 | 171,702 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:34 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
6,945 | $52.9 | 152,408 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:34 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
6,945 | $0 | 152,408 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,087 | $52.9 | 26,797 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:32 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,087 | $0 | 26,797 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
9,260 | $52.9 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $14.37 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
9,260 | $0 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:31 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
903 | $14.37 | 353,887 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,556 | $52.9 | 39,203 (Direct) |
View |
| 2019-02-27 Exercise |
2019-03-01 4:30 pm |
2019-02-27 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,556 | $0 | 39,203 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 6:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
31,200 | $53.38 | 177,758 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 6:00 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
31,200 | $0 | 177,758 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:58 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
43,333 | $53.38 | 80,482 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:58 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
43,333 | $0 | 80,482 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:57 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
36,400 | $53.38 | 145,463 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:57 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
36,400 | $0 | 145,463 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,000 | $53.38 | 30,087 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:56 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,000 | $0 | 30,087 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:54 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
21,667 | $53.38 | 42,972 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:54 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
21,667 | $0 | 42,972 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
53,333 | $53.38 | 224,497 (Direct) |
View |
| 2019-02-22 Exercise |
2019-02-26 5:51 pm |
2019-02-22 N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
53,333 | $0 | 224,497 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
32,098 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
17,902 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
32,098 | $11.46 | 203,262 (Direct) |
View |
| 2019-02-12 Exercise |
2019-02-14 5:10 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
17,902 | $11.46 | 203,262 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Mon, 20 May 2019 22:00:02 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |